Recursion Reaches FDA Agreement on Primary Endpoint for Phase III FAP Trial

Recursion Pharmaceuticals has reached an agreement with the U.S. Food and Drug Administration on the primary endpoint for an upcoming global Phase III trial of REC-4881, an experimental treatment for familial adenomatous polyposis, CEO Najat Khan announced at the Jefferies Healthcare Conference in London, TradingView reported.

The registrational study is on track to begin in the second half of 2027 and will enroll approximately 200 adult patients who have had their colons removed, according to company releases carried by TradingView and Recursion Pharmaceuticals. Familial adenomatous polyposis, commonly known as FAP, is a rare inherited disease characterized by the development of numerous gastrointestinal polyps carrying a high risk of progression to cancer.

Currently, there are no approved pharmacologic therapies for the condition, leaving patients dependent on frequent endoscopic surveillance and surgical interventions. Khan estimated the potential market for a successful treatment at $15 billion, encompassing more than 50,000 patients across the United States and five major European markets.

Plain English Guide to the Clinical Trial

  • What is REC-4881? It is an investigational oral MEK1/2 inhibitor, meaning it is a pill designed to block specific cellular signaling pathways that drive abnormal cell growth and polyp formation.
  • What is the Primary Endpoint? The trial will measure event-free survival using a composite endpoint that includes dysplasia, specific surgeries, cancer, death, and the surgical excision of any polyp measuring 10 millimeters or larger anywhere in the gastrointestinal tract.
  • Why does polyp size matter? Adenomas reaching 10 millimeters or greater carry a significantly elevated risk of high-grade dysplasia and malignant transformation. Counting their removal as an event establishes a direct clinical benchmark for preventing cancer progression.

Clinical Background and Phase II Results

The progression toward a global registrational study follows Phase II data from post-colectomy patients treated with REC-4881. In that trial, approximately one in three patients experienced a reduction of more than 65% in total polyp burden, evaluated by both size and number, after 13 weeks of therapeutic intervention.

Reductions were observed across both the upper and lower gastrointestinal tracts, and most of the reduction was sustained in patients monitored for three months after cessation of treatment. Khan highlighted one documented case where a patient’s count of upper gastrointestinal polyps larger than 5 millimeters dropped from 96 to just one over the 13-week period.

Medical experts emphasize that surgery does not eliminate the systemic nature of the condition. “Patients with familial adenomatous polyposis face a lifelong burden of endoscopic surveillance, repeated interventions, and frequently major surgery,” said Dr. Robert Hüneburg, Senior Gastroenterologist and Head of the Hereditary Tumor Clinic at the University Hospital Bonn in Germany, in a statement published by Recursion.

Dr. Evelien Dekker, Professor of Gastrointestinal Oncology at Amsterdam University Medical Center, noted the physical toll of standard management in statements provided to Recursion. “Adenomas 10 millimeters and larger are associated with increased cancer risk and are nowadays routinely removed in patients with FAP. However, removal carries risks of bleeding and perforation, alongside the burden of repeated procedures and intensive surveillance,” Dekker said.

Trial Parameter Phase II Findings / Details Phase III Study Design
Patient Population Post-colectomy FAP patients Approximately 200 adults post-colectomy or proctocolectomy
Efficacy Benchmark ~1 in 3 saw >65% reduction in polyp burden Composite event-free survival (dysplasia, surgery, cancer, death, excision of polyps ≥10 mm)
Secondary Measures Size and number evaluations across upper and lower GI tracts Modified Spigelman stage progression and total polyp burden
Timeline Evaluated after 13 weeks of treatment Global registrational study on track to begin in second half of 2027

Platform Technology and Pipeline Expansion

Recursion utilized its proprietary artificial intelligence platform, known as Recursion OS, to identify the biological rationale for testing REC-4881 in FAP through unbiased phenotypic screening. The company is also advancing other oncology programs developed through its computational foundation models.

Recursion is actively recruiting for an endometrial cancer expansion cohort and anticipates sharing early monotherapy data encompassing a handful of patients in the second half of 2027. The tolerability profile observed to date includes manageable grades one and two fatigue and anemia around the 45-milligram daily dose.

Contraindications & When to Consult a Doctor

Experimental therapies such as REC-4881 and REC-1245 remain investigational and are restricted to clinical trial participants meeting strict inclusion and exclusion criteria. Patients diagnosed with familial adenomatous polyposis or solid tumors should not seek out these compounds outside of formal, institutional review board-approved clinical studies.

Individuals undergoing endoscopic surveillance for hereditary polyposis syndromes must consult their gastroenterologists or hereditary tumor specialists immediately if they experience acute warning signs, including severe abdominal pain, persistent rectal or gastrointestinal bleeding, unexplained fever, or sudden changes in bowel habits. Standard clinical management—including scheduled colectomies, proctocolectomies, and routine endoscopies—remains the established medical standard of care.

Financial Structure and Subsequent Milestones

The company reported that its broader research and development efforts are supported by major pharmaceutical partnerships, including agreements with Sanofi and Roche Genentech. Sanofi recently optioned an oral dual-inhibitor molecule designed via Recursion’s platform, while Roche Genentech has secured options on novel targets from the company’s biological maps.

Across all active partnerships, Recursion has surpassed approximately $535 million in cash inflows, as reported by TradingView. Management said that the company has reduced its operating cash burn by 40% and successfully completed an oversubscribed financing round to sustain its clinical pipeline.

Global clinical development for REC-4881 will proceed toward the initiation of the registrational study in the second half of 2027, with additional timeline details expected from company leadership as trial activation approaches.

References

  • Recursion Pharmaceuticals. “Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis.” November 18, 2026.
  • TradingView. Coverage of Jefferies Healthcare Conference presentation by CEO Najat Khan. November 2026.

Photo of author

Health Desk

Health Desk at Archyde.

UFC Qatar in Doha features Procházka vs. Stirling on November 21